Yuhan Corporation's Q3 Operating Profit Surges 690%
Yuhan Corporation’s third-quarter operating profit has skyrocketed, primarily due to license revenue from its out-licensed non-small cell lung…
LECLAZA
3 개의 기사가 있습니다.
Who Led LECLAZA-RYBREVANT Combination Therapy Clinical Trial and Achieved FDA Approval?
"When coincidences accumulate, they become inevitable. The fact that LECLAZA, which I once crossed paths with, came back…
Leclaza Combination Therapy Study Published in NEJM, Raising Expectations for FDA Approval
A study demonstrating the superior efficacy of the combination therapy of Yuhan Corporation's non-small cell lung cancer (NSCLC)…